ReviewCancer management and research2018

Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?

Gaurav GoelPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.